10-K: BioRegenx Reports Significant Losses in 2024, Cites Product Issues and Increased Expenses

BioRegenx, Inc. reports a substantial net loss of $23.05 million for the year ended December 31, 2024, driven by decreased sales, amortization and impairment expenses.

Summary

• BioRegenx, Inc. reported a net loss of $23.05 million for the year ended December 31, 2024, compared to a net loss of $3.60 million in 2023.
• Gross sales decreased by 29% to $2.60 million in 2024 from $3.69 million in 2023, attributed to product issues with the medical testing machine.
• Operating expenses significantly increased to $24.42 million in 2024 from $5.72 million in 2023, including amortization expense of $2.18 million and impairment expense of $16.21 million.
• The company acquired DocSun Biomedical Holdings, Inc. on January 8, 2024, and merged with Findit, Inc. on March 8, 2024.
• BioRegenx is focusing on expanding its sales and marketing efforts, including new online sales channels, and developing health and wellness apps.
• The company acknowledges substantial doubt about its ability to continue as a going concern without additional financing.
• The company is involved in disputes with certain parties, including former officers and board members, and vendors associated with their activities and contractual matters.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant losses, decreased sales, and concerns about the company's ability to continue as a going concern. While there are some positive developments, the overall financial situation is concerning.

Positives

• The company is actively developing health and wellness apps, including TruScan.Ai and VitalWellness.
• BioRegenx is expanding its sales and marketing efforts through new online channels like Amazon and Walmart.
• The company secured favorable financing options for GlycoCheck customers to improve accessibility.
• The company is working to enhance AI capabilities through new hardware and software development.

Negatives

• The company experienced a significant decrease in gross sales due to product issues.
• Operating expenses increased substantially due to amortization and impairment expenses.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is in default on certain notes payable totaling $522,500.
• The company is involved in disputes with certain parties, including former officers and board members.

Risks

• The company's ability to continue as a going concern is contingent upon obtaining additional financing.
• The company faces intense competition in the health, wellness, and anti-aging markets.
• The company is subject to the penny stock rules, which may reduce trading activity.
• The company acknowledges material weaknesses in its internal control over financial reporting.
• The company is involved in disputes with certain parties, including former officers and board members, and vendors associated with their activities and contractual matters.

Future Outlook

The company is intensifying its sales and marketing efforts, developing health and wellness apps, and seeking additional financing to fund ongoing operations and working capital.

Management Comments

• Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital.
• Management has yet to find a solution to its funding requirements.

Industry Context

The global healthcare market is experiencing significant growth, driven by advancements in medical technology and an aging population, with telehealth seeing accelerated adoption.

Comparison to Industry Standards

• The report mentions competition from major technology and digital marketing companies such as Alphabet Inc. (Google), Microsoft Corporation, Meta Platforms (Facebook, Instagram), X Corp. (formerly Twitter), and Zillow.
• The company competes with leading telehealth players such as Teladoc Health, Amwell, and MDLIVE.
• The company's competitive differentiation is driven by its proprietary AI technology and strategic partnerships with healthcare providers.

Legal Proceedings

• The Company is involved in disputes with certain parties, including parties that are former officers and board members and vendors associated with their activities and contractual issues.

Related Party Transactions

• The company rents its home office from BBD Holdings, LLC, which is controlled by Joseph Bird, a significant shareholder and spouse of a director.
• The company reimburses certain officers and board members for company expenses paid through individual credit cards.
• Certain related party loans are secured by all assets of the Company or all assets of a subsidiary.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may experience disruptions due to product issues and potential financial instability.

Next Steps

• The company plans to intensify its sales and marketing efforts.
• The company will continue developing health and wellness apps.
• The company intends to raise additional debt or equity financing.

Key Dates

Keywords

BioRegenx, financial results, 10-K, DocSun, Findit, acquisition, merger, net loss, impairment, going concern, medical devices, nutritional products, telehealth, AI, internal control